NCT03199963: A trial that was reported late by BHR Pharma, LLC
This trial has reported, although it was 612 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03199963 |
|---|---|
| Title | A Randomized, Double-blind, Placebo Controlled Trial of 4-Hydroxytamoxifen Gel for Reducing Breast Tissue Density in Women With BI-RADS Breast Density Categories C or D |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 21, 2017 |
| Completion date | Jan. 14, 2019 |
| Required reporting date | Jan. 14, 2020, midnight |
| Actual reporting date | Sept. 17, 2021 |
| Date last checked at ClinicalTrials.gov | Oct. 19, 2026 |
| Days late | 612 |